Uhlenhopp DJ, Then EO, Sunkara T et al (2020) Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 13:1010–1021

Article  PubMed  Google Scholar 

Ilson DH, van Hillegersberg R (2018) Management of patients with adenocarcinoma or squamous cancer of the esophagus. Gastroenterology 154:437–451

Article  PubMed  Google Scholar 

Eyck BM, van Lanschot JJB, Hulshof M et al (2021) Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled cross trial. J Clin Oncol 39:1995–2004

Article  CAS  PubMed  Google Scholar 

van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084

Article  PubMed  Google Scholar 

Matsuda S, Kitagawa Y, Takemura R et al (2022) Real-world evaluation of the efficacy of neoadjuvant dcf over cf in esophageal squamous cell carcinoma: propensity score matched analysis from 85 authorized institutes for esophageal cancer in japan. Ann Surg 278:e35

Article  PubMed  Google Scholar 

Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715

Article  CAS  PubMed  Google Scholar 

Yokota T, Kato K, Hamamoto Y et al (2016) Phase ii study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer 115:1328–1334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of wbc growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33:3199–3212

Article  CAS  PubMed  Google Scholar 

Curran MP, Goa KL (2002) Pegfilgrastim. Drugs 62:1207–1213 (discussion 1214–1205)

Article  CAS  PubMed  Google Scholar 

Maeda O, Fukaya M, Koike M et al (2022) Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: a phase ii study. Asia Pac J Clin Oncol 18:578–585

Article  PubMed  Google Scholar 

Ishikawa T, Yasuda T, Okayama T et al (2019) Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: a phase ii study. Cancer Sci 110:3754–3760

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schnipper LE, Davidson NE, Wollins DS et al (2015) American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33:2563–2577

Article  PubMed  PubMed Central  Google Scholar 

Obermannova R, Alsina M, Cervantes A et al (2022) Oesophageal cancer: Esmo clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:992–1004

Article  CAS  PubMed  Google Scholar 

Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39(Suppl 1):S32-37

Article  PubMed  Google Scholar 

Yamasaki M, Miyata H, Tanaka K et al (2011) Multicenter phase i/ii study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology 80:307–313

Article  CAS  PubMed  Google Scholar 

Takahashi H, Arimura Y, Yamashita K et al (2010) Phase i/ii study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 5:122–128

Article  PubMed  Google Scholar 

Osaka Y, Shinohara M, Hoshino S et al (2011) Phase ii study of combined chemotherapy with docetaxel, cddp and 5-fu for highly advanced esophageal cancer. Anticancer Res 31:633–638

CAS  PubMed  Google Scholar 

Noronha V, Joshi A, Jandyal S et al (2014) High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (dcf) combination chemotherapy for locally advanced esophageal and junctional cancer. Med Oncol 31:188

Article  PubMed  Google Scholar 

Patel K, West HJ (2017) Febrile neutropenia. JAMA Oncol 3:1751

Article  PubMed  Google Scholar 

Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266

Article  PubMed  Google Scholar 

Lyman GH (2005) Guidelines of the national comprehensive cancer network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 3:557–571

Article  PubMed  Google Scholar 

Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475–2484

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of eortc guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32

Article  CAS  PubMed  Google Scholar 

Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage ii or stage iii/iv breast cancer. J Clin Oncol 20:727–731

Article  CAS  PubMed  Google Scholar 

Kawahira M, Yokota T, Hamauchi S et al (2018) Primary prophylactic granulocyte colony-stimulating factor according to asco guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Int J Clin Oncol 23:1189–1195

Article  CAS  PubMed  Google Scholar 

Yoshida Y, Komori K, Aoki M et al (2018) Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. Pharmazie 73:613–616

CAS  PubMed  Google Scholar 

Ma X, Kang J, Li Y et al (2021) Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis. BMJ Support Palliat Care:bmjspcare-2020-002532

Linot B, Augereau P, Breheret R et al (2014) Efficacy and safety of early g-csf administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (dcf protocol): a retrospective study. Support Care Cancer 22:2831–2837

Article  CAS  PubMed  Google Scholar 

Endo Y, Ishikawa T, Oka K et al (2022) Effect of concomitant use of g-csf and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model. Med Oncol 39:110

Article  CAS  PubMed  Google Scholar 

Janoray G, Pointreau Y, Garaud P et al (2016) Long-term results of a multicenter randomized phase iii trial of induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation. J Natl Cancer Inst 108:djv368. https://doi.org/10.1093/jnci/djv368

Article  CAS  PubMed  Google Scholar 

Posner MR, Norris CM, Wirth LJ et al (2009) Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in tax 324: Survival, surgery, and organ preservation. Ann Oncol 20:921–927

Article  CAS  PubMed  Google Scholar 

Cho H, Nishiike S, Yamamoto Y et al (2015) Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx 42:396–400

Article  PubMed  Google Scholar 

Takenaka Y, Cho H, Yamamoto M et al (2013) Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. Support Care Cancer 21:2861–2868

Article  PubMed  Google Scholar 

Schuman SI, Lambrou N, Robson K et al (2009) Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 7:225–228

CAS  PubMed  Google Scholar 

Whitworth JM, Matthews KS, Shipman KA et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112:601–604

Article  CAS  PubMed  Google Scholar